Therapy of small cell lung cancer with emphasis on oral topotecan

被引：12

作者：

Pirker, Robert ^{[1
]}

Berzinec, Peter ^{[2
]}

Brincat, Stephen ^{[3
]}

Kasan, Peter ^{[4
]}

Ostoros, Gyula ^{[5
]}

Pesek, Milos ^{[6
]}

Plate, Signe ^{[7
]}

Purkalne, Gunta ^{[8
]}

Rooneem, Regina ^{[9
]}

Skrickova, Jana ^{[10
]}

Stanculeanu, Dana ^{[11
]}

Timcheva, Constanta ^{[12
]}

Tzekova, Valentina ^{[13
]}

Zakotnik, Branko ^{[14
]}

Zielinski, Christoph C. ^{[1
]}

Zwitter, Matjaz ^{[15
]}

机构：

[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria

[2] Specialised Hosp St Zoerardus Zobor, Dept Oncol, Nitra, Slovakia

[3] Sir Paul Boffa Hosp, Floriana, Malta

[4] Univ Hosp Bratislava, Dept Oncol, Bratislava, Slovakia

[5] Natl Koranyi Inst TB & Pulmonol, Budapest, Hungary

[6] Charles Univ Prague, Fac Med, Plzen, Czech Republic

[7] Riga Easten Univ Hosp, Riga, Latvia

[8] Paul Stradins Clin Univ Hosp Riga, Radiat & Chemotherapy Ctr, Riga, Latvia

[9] N Estonia Reg Hosp, Ctr Canc, Dept Chemotherapy, Tallinn, Estonia

[10] Univ Hosp, Dept Resp Dis & TB, Brno, Czech Republic

[11] Inst Oncol, Bucharest, Romania

[12] Specialized Hosp Active Treatment Oncol, Sofia, Bulgaria

[13] ISUL, Univ Hosp Queen Joanna, Clin Chemotherapy, Sofia, Bulgaria

[14] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia

[15] Inst Oncol Ljubljana, Dept Radiat Oncol, Ljubljana, Slovenia

来源：

LUNG CANCER | 2010年 / 70卷 / 01期

关键词：

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan; PROPHYLACTIC CRANIAL IRRADIATION; PREVIOUSLY UNTREATED PATIENTS; CISPLATIN PLUS ETOPOSIDE; LONG-TERM SURVIVAL; PHASE-III TRIAL; PROGNOSTIC-FACTORS; THORACIC RADIOTHERAPY; 2ND-LINE TREATMENT; CHEMOTHERAPY; AMRUBICIN;

D O I：

10.1016/j.lungcan.2010.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：7 / 13

页数：7

共 50 条

[1] Topotecan as salvage therapy of refractory small cell lung cancer
Hatabay, Nilgun
Erdal, Nuray
Ece, Ferah
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S813 - S813
[2] Topotecan (Hycamtin®) in the therapy of small-cell lung cancer
Manegold, C
ONKOLOGIE, 1998, 21 : 13 - 17
[3] Topotecan in small cell lung cancer
Schiller, JH
SEMINARS IN ONCOLOGY, 1997, 24 (06) : S27 - S33
[4] Topotecan in small cell lung cancer
Campling, B
CANCER BIOLOGY & THERAPY, 2004, 3 (01) : 94 - 95
[5] Topotecan as first-line therapy for small cell lung cancer
Greco, FA
LUNG CANCER, 2003, 41 : S9 - S16
[6] Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Eckardt, J. R.
Ramlau, R.
Gervais, R.
Shepherd, F.
O'Brien, M.
Ciuleanu, T.
Dharan, B.
Wissel, P.
Ross, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 387S - 387S
[7] Treatment Related Side Effects of Oral Topotecan in Small Cell Lung Cancer
Popovic, Filip
Jakopovic, Marko
Samarzija, Miroslav
Cucevic, Branka
Kukulj, Suzana
Roglic, Mihovil
Plestina, Sanja
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S703 - S703
[8] Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy
Eckardt, JR
ONCOLOGY, 2001, 61 : 42 - 46
[9] Topotecan for the treatment of small-cell lung cancer
Nicum, Shibani J.
O'Brien, Mary E. R.
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) : 795 - 801
[10] Status of topotecan in small-cell lung cancer
Drings, P
Stahel, R
ONKOLOGIE, 2000, 23 : 1 - 1

← 1 2 3 4 5 →